Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

This activity was originally presented as a part of Immunology Specialty Pharmacy Day of Education 2025.

Program Description

This session will address the significant challenges in managing moderate to severe atopic dermatitis (AD) in pediatric patients, including its incidence, burdensome impact on patient and caregiver quality of life, and characteristic symptoms. Through an in-depth exploration of the underlying pathophysiology, particularly type 2 inflammation and associated comorbidities, the session will explore the evolution of treatment approaches and the persistent unmet clinical needs that biologics aim to address. Participants will gain a thorough understanding of the role of approved and emerging biologic therapies that target type 2 inflammation, alongside updated clinical guidelines and the limitations of topical treatments in AD. The program will also focus on the practical aspects of integrating biologic therapy into management strategies, emphasizing patient-specific indications, appropriate use, and crucial specialty pharmacy considerations such as patient counseling, therapy initiation, individualized selection, multidisciplinary collaboration, access, and ongoing monitoring and optimization of treatment. An included Powered by Patients interview will provide additional insight into the burdensome impact of AD on patients' and caregivers' quality of life.

Target audience: Specialty Pharmacist

Type of activity: Application
Release date: July 31, 2025
Expiration date: July 31, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the quality of life burden associated with uncontrolled moderate to severe pediatric atopic dermatitis (AD)
• Analyze the safety and efficacy of biologic therapies in pediatric patients with AD
• Apply evidence-based guidelines to select appropriate biologic therapies for pediatric patients with moderate to severe AD 4. Investigate strategies to address caregiver concerns and barriers to biologic therapy initiation and adherence in pediatric patients with AD